Eyenovia reports third quarter 2023 financial results and provides business update

Acquired u.s. commercial rights to app13007, currently under fda review for post-surgical ocular pain and inflammation, from formosa pharmaceuticals
EYEN Ratings Summary
EYEN Quant Ranking